COVID-19 thromboprophylaxis. New evidence
Description
Recent publications have questioned the efficacy of using therapeutic or intermediate doses of low molecular weight heparin in COVID-19 patients, especially in the most severe patients. In order to update these recommendations, a non-systematic
